Filed with ASX · · 3 pages · English
Atomo Diagnostics Ltd. has filed the Chairman's Address to Shareholders for its Annual General Meeting, detailing the company's performance and strategic direction. The address highlights a transitional year for Atomo, emphasizing growth in its HIV franchise and advancements in product development. The Chairman also acknowledges the leadership transition to Dr. Cheri Walker and outlines the company's commitment to innovation in diagnostic testing. The Board expresses confidence in Atomo's technology and strategic partnerships as key drivers for future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX Announcement 5 November 2026 2026 Annual General Meeting – Chairman’s Address to Shareholders In accordance with ASX Listing Rule 3.13.3, Atomo Diagnostics Limited (Atomo) attaches the Chairman’s Address to be delivered at Atomo’s 2026 Annual General Meeting. For more information,...
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics